# Study Evaluating the Efficacy, Safety, and Tolerability of ASY202 (Dihydroergotamine Mesylate [DHE] Inhalation Powder Delivered Via a Multidose Dry Powder Inhaler) for the Acute Treatment of Migraine in Adult Patients

> **NCT07646613** · PHASE2 · RECRUITING · sponsor: **Aspeya, Inc.** · enrollment: 108 (estimated)

## Conditions studied

- Migraine

## Interventions

- **COMBINATION_PRODUCT:** ASY202
- **COMBINATION_PRODUCT:** Placebo

## Key facts

- **NCT ID:** NCT07646613
- **Lead sponsor:** Aspeya, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-05-19
- **Primary completion:** 2027-03
- **Final completion:** 2027-03
- **Target enrollment:** 108 (ESTIMATED)
- **Last updated:** 2026-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07646613

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07646613, "Study Evaluating the Efficacy, Safety, and Tolerability of ASY202 (Dihydroergotamine Mesylate [DHE] Inhalation Powder Delivered Via a Multidose Dry Powder Inhaler) for the Acute Treatment of Migraine in Adult Patients". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07646613. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*